Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 2, 2011, Pages 225-229

  Vlase, L ^a   Neag, M ^a   Popa, A ^a   Muntean, D ^a   Baldea I ^b   Leucuta, S E ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b BABE BOLYAI UNIVERSITY   (Romania)

Author keywords

carbamazepine; drug interaction; ivabradine; pharmacokinetics

Indexed keywords

CARBAMAZEPINE; IVABRADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; SINGLE DRUG DOSE;

ADULT; ANTICONVULSANTS; AREA UNDER CURVE; BENZAZEPINES; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; CARDIOVASCULAR AGENTS; DRUG INTERACTIONS; HALF-LIFE; HEART RATE; HUMANS; MALE; YOUNG ADULT;

EID: 79952257540     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01170.x     Document Type: Article

References (15)

1. Prasad UK, Gray D, Purcell H, (2009) Review of the I-f selective channel inhibitor ivabradine in the treatment of chronic stable angina. Advances in Therapy, 26, 127-137.
2. Khawaja MZ, Walker DM, (2009) Ivabradine-the beauty of a slow heart rate. International Journal of Clinical Practice, 63, 542-546.
3. Tardif JC, Ponikowski P, Kahan T, (2009) Efficacy of the I-f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. European Heart Journal, 30, 540-548.
4. Milliez P, Messaoudi S, Nehme J, et al. (2009) Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. American Journal of Physiology-Heart and Circulatory Physiology, 296, H435-H441.
5. Riccioni G, Vitulano N, D'Orazio N, (2009) Ivabradine: beyond heart rate control. Advances in Therapy, 26, 12-24.
6. Portoles A, Calvo A, Terleira A, et al. (2006) Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. Journal of Clinical Pharmacology, 46, 1195-1203. (Pubitemid 44387420)
7. Portoles A, Terleira A, Calvo A, (2006) Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. Journal of Clinical Pharmacology, 46, 1188-1194. (Pubitemid 44387419)
8. Patsalos PN, Fröscher W, Pisani F, van Rijn CM, (2002) The importance of drug interactions in epilepsy therapy. Epilepsia, 43, 365-385. (Pubitemid 34297175)
9. Ji P, Damle B, Xie FD, et al. (2008) Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. Journal of clinical pharmacology, 48, 948-956. (Pubitemid 352009496)
10. Vlase L, Muntean D, Leucuta SE, Baldea I, (2009) High-throughput determination of ivabradine from human plasma by LC/MS/MS and its application to pharmacokinetic studies. Studia Universitatis Babes-Bolyai Chemia, 54, 43-52.
11. Thermo Scientific Kinetica -Pharmacokinetic/Pharmacodynamic (PK/PD) data analysis, simulation and reporting system. Available at: (accessed 5 March 2010).
12. Schuirmann DJ, (1987) A comparison of the 2 one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics, 15, 657-680.
13. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. (2003) Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administrated Drug Products-General Considerations. Rockville, USA: FDA. Available at: (accessed 5 March 2010).
14. The European Agency for the Evaluation of Medicinal Products. (2001) Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London, UK. (CPMP/EWP/QWP/1401/98).
15. Lamba JK, Lin YS, Schuetz EG, Thummel KE, (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Advanced Drug Delivery Reviews, 54, 1271-1294. (Pubitemid 35284253)